

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, December 10, 2021

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	-	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	-
Mikel Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard, DSS Staff	X
Lenny Petrik, PharmD	X	Sarah Aker, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:05 pm. The minutes of the September meeting were presented. Oehlke made a motion to approve. Ladwig seconded the motion. The motion was unanimously approved.

Jockheck made an announcement to the committee welcoming Sarah Aker back as the new Medicaid Director since Bill Synder's departure, the previous Medicaid Director, at the last meeting.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2021 to September 30, 2021. A total of 1,712 PAs were reviewed of which 141 requests (8.2%) were received via telephone and 914 requests (53.4%) were received via fax, and 657 (38.4%) were reviewed via electronically. There was a 17.7% increase of PAs received from the previous quarter. Analgesics-opioids decreased to the fourth spot on the Top Therapeutic Classes reviewed for PA.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2021 to September 30, 2021. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, cystic fibrosis correctors, skin and mucous membrane agents, and anticonvulsants. These top 15 therapeutic classes make up 24.59 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.19 % of total claims. Under the top drugs based on number of claims, the top increases were covid vaccines and albuterol utilization. Van Gilder commented the increase in albuterol could be associated with the increase in RSV infections. The big decreases in number of claims were hydrocodone and tramadol. Under the top drugs by paid amount, due to the decrease in HIV utilization of single agent drugs for multi-class combination drugs, there was an increase in utilization of Biktarvy during this quarter. Darger requested Humira pen and Humira combined going forward.

Old Business

Pancreatic enzyme utilization

The committee continued the review on the utilization of pancreatic enzymes specifically the average quantity per prescription. Darger commented on the price increase of these drugs. The utilization looked appropriate.

Review PA forms and criteria

The committee reviewed utilization of drugs on PA that are available as generics now. After review, the committee decided on the following:

- Uloric – keep PA on both brands and generics
- Antihistamines – keep PA on ODT, chewables, and Clarinex syrup since children under 12 years old and patients with dysphagia bypass the PA

Darger inquired if there was any public comment. There were none.

Hepatitis C update

Aker gave an update on the department's efforts to implement the committee's hepatitis C recommendations with consideration of the overall budget and monitoring of community health. Nathan Blake from AbbVie provided public comment. Becky Klemme, RN, from Avera Liver Clinic provided public comment. Tami Hogue-Lorenzen, Chief Medical Officer for South Dakota Urban City and Health, provided public comment. Dr. Doug Lehmann, MD, internal medication pediatric doctor in Rapid City at the Community Health Center at Black Hills provided public comment. Preuss, Petrik, Holland, and Darger also provided feedback.

Opioid update

The committee reviewed 3Q2021 opioid outcomes compared to previous quarters from the opioid initiatives. There was a slight increase in opioid utilization and opioid utilizers during third quarter which corresponds to the increase in total eligible members and total drug utilization, but the number of utilizers exceeding 180 MED/day decreased.

New Business

Antineoplastic oral drugs

Committee reviewed utilization of antineoplastic oral drugs. Nearly half the pipeline of new drugs in development are geared towards oncology related medications. Oral oncology drugs account for 3.3% of total plan paid. Committee also discussed the pros and cons of managing the more expensive oral oncology drugs with a shorter 15 day fill for the first 90 days for new starts only to avoid medication waste if a drug is not well tolerated. The cons entailed the rural nature of the state, some drugs requiring the original container for dispensing, and hardship of some members driving to the pharmacy for two fills in one month.

Anticonvulsants

Committee reviewed utilization of anticonvulsants for appropriate use. Several anticonvulsants had label indications for various mental health disorders. There was an in-depth review for appropriate use for those anticonvulsants without the label indication for mental health disorders. Based on the utilization and available diagnosis codes, utilization seemed appropriate.

Darger inquired if there was any public comment. There were none.

Gastrointestinal drugs

Committee reviewed the utilization of gastrointestinal drugs as a follow up to the in-depth review of Cholbam at the last meeting. Utilization and current PAs all were appropriate.

Insulin quantity

Committee reviewed the utilization of insulins and current quantity limits. Van Gilder provided expertise on utilization and potential quantity limits for the long-acting insulins. Jockheck inquired if setting a limit of 45 ml for pens and 50 ml for vials were appropriate. Van Gilder agreed. Darger inquired since Lantus and Semglee are bio-identical for these to be interchangeable. Jockheck will confirm on MAC pricing.

JAK inhibitor criteria

Committee reviewed the safety updates for increased risk of serious heart-related events and class-wide update and label for all three oral JAK inhibitors: Xeljanz/XR, Olumiant, and Rinvoq. There was discussion to update the PA criteria for all the oral JAK inhibitors for patients who have had an inadequate response to, intolerance to one or more TNF blockers. VanGilder made the motion to update the criteria with the class-wide update to the labeling. Holland seconded the motion. The motion was unanimously approved.

Darger inquired if there was any public comment. There were none.

Trudhesa

Trudhesa clinical information was presented for review. Committee decided to monitor utilization. Darger inquired if there was any public comment. There were none.

Adjournment

The next meeting is scheduled on March 4, 2022. The June meeting is tentatively scheduled on June 10, 2022. Holland made a motion to adjourn the meeting, and everyone seconded the motion. The motion passed unanimously, and the meeting adjourned at 2:30 pm.